JP2022505107A - キメラ分子 - Google Patents

キメラ分子 Download PDF

Info

Publication number
JP2022505107A
JP2022505107A JP2021521016A JP2021521016A JP2022505107A JP 2022505107 A JP2022505107 A JP 2022505107A JP 2021521016 A JP2021521016 A JP 2021521016A JP 2021521016 A JP2021521016 A JP 2021521016A JP 2022505107 A JP2022505107 A JP 2022505107A
Authority
JP
Japan
Prior art keywords
cell
peptide
cells
antigen
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021521016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505107A5 (https=
Inventor
ヤン キズィエロフ，
フランツ ヨーゼフ オバーマイヤー，
マンフレート コップフ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eidgenoessische Technische Hochschule Zurich ETHZ
Original Assignee
Eidgenoessische Technische Hochschule Zurich ETHZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eidgenoessische Technische Hochschule Zurich ETHZ filed Critical Eidgenoessische Technische Hochschule Zurich ETHZ
Publication of JP2022505107A publication Critical patent/JP2022505107A/ja
Publication of JP2022505107A5 publication Critical patent/JP2022505107A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
JP2021521016A 2018-10-19 2019-10-18 キメラ分子 Pending JP2022505107A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18201560 2018-10-19
EP18201560.2 2018-10-19
PCT/EP2019/078449 WO2020079264A1 (en) 2018-10-19 2019-10-18 Chimeric molecules

Publications (2)

Publication Number Publication Date
JP2022505107A true JP2022505107A (ja) 2022-01-14
JP2022505107A5 JP2022505107A5 (https=) 2022-10-24

Family

ID=63965155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521016A Pending JP2022505107A (ja) 2018-10-19 2019-10-18 キメラ分子

Country Status (12)

Country Link
US (1) US20210324037A1 (https=)
EP (1) EP3867268A1 (https=)
JP (1) JP2022505107A (https=)
KR (1) KR20210081345A (https=)
CN (1) CN112930355A (https=)
AU (1) AU2019362400A1 (https=)
BR (1) BR112021007418A2 (https=)
CA (1) CA3115007A1 (https=)
EA (1) EA202191083A1 (https=)
IL (1) IL282230A (https=)
MX (1) MX2021004355A (https=)
WO (1) WO2020079264A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109321569B (zh) * 2018-10-29 2022-04-12 迈杰转化医学研究(苏州)有限公司 一种引物探针组合物及其应用
EP4638712A2 (en) * 2022-12-22 2025-10-29 Bluesphere Bio, Inc. Methods for identifying t cell receptors (tcrs) that bind antigens

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514765A (ja) * 1998-05-11 2002-05-21 ミルテニィ バイオテック ゲーエムベーハー 抗原特異的ｔ細胞の直接的選択方法
JP2017537642A (ja) * 2014-12-19 2017-12-21 イーティーエッチ チューリッヒ キメラ抗原受容体及びその使用方法
JP2018038388A (ja) * 2013-08-05 2018-03-15 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｎｓｃｌｃをはじめとする肺がんなどの数種の腫瘍に対する新規免疫療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160177284A1 (en) * 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
CN107223051B (zh) * 2014-12-17 2021-09-03 斯坦福国际研究院 抗原递送系统
CN105504018B (zh) * 2016-01-13 2019-01-04 郑州大学 Lag-3亲和肽n13、制备方法及其应用
CN107286246B (zh) * 2016-12-28 2019-12-17 时力生物科技（北京）有限公司 治疗脑胶质瘤的嵌合抗原受体修饰的树突状细胞及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514765A (ja) * 1998-05-11 2002-05-21 ミルテニィ バイオテック ゲーエムベーハー 抗原特異的ｔ細胞の直接的選択方法
JP2018038388A (ja) * 2013-08-05 2018-03-15 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｎｓｃｌｃをはじめとする肺がんなどの数種の腫瘍に対する新規免疫療法
JP2017537642A (ja) * 2014-12-19 2017-12-21 イーティーエッチ チューリッヒ キメラ抗原受容体及びその使用方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AL-JAUFY: "Cytotoxicity of a Shiga toxin A subunit-CD4 fusion protein to human immunodeficiency vir", INFECTION AND IMMUNITY, vol. 62, JPN6023045745, 1994, pages 956 - 60, ISSN: 0005335229 *
AL-JAUFY: "Purification and characterization of a shiga toxin A subunit-Cd4 fusion protein cytotoxic", INFECTION AND IMMUNITY, vol. 63, JPN6023045744, 1995, pages 3073 - 8, ISSN: 0005335228 *
GIANLUCA PETRIS: "CD4 and BST-2/Tetherin Proteins Retro-translocate from Endoplasmic Reticulum to Cytosol ", J. BIOL CHEMI, vol. 289, JPN6023045743, 2014, pages 1 - 12, ISSN: 0005335227 *
SEBASTIAN BREUER: ""Molecular Design, Functional Characterization and Structural Basis of a Protein Inhibitor", PLOS ONE, vol. 6, JPN6023045746, 2011, pages 20033, ISSN: 0005335230 *
TOMOAKI YOSHIKAWA: "Development of Amphiphilic ?A-PGA Based Antigen Delivery Carrier for Cancer Immunotherapy", J. SOC. POWDER TECHNOL., JAPAN, vol. 44, JPN6023045747, 2007, pages 386, ISSN: 0005335231 *

Also Published As

Publication number Publication date
MX2021004355A (es) 2021-05-31
IL282230A (en) 2021-05-31
WO2020079264A1 (en) 2020-04-23
AU2019362400A1 (en) 2021-04-22
EP3867268A1 (en) 2021-08-25
US20210324037A1 (en) 2021-10-21
EA202191083A1 (ru) 2021-07-23
BR112021007418A2 (pt) 2021-08-10
CA3115007A1 (en) 2020-04-23
CN112930355A (zh) 2021-06-08
KR20210081345A (ko) 2021-07-01

Similar Documents

Publication Publication Date Title
US20250043011A1 (en) T Cell Modification and Use Thereof
JP6482461B2 (ja) 投与に関する形質導入ｔ細胞の適合性の評価方法
CN104853765B (zh) 肿瘤特异性t细胞受体
US11987613B2 (en) Isolated T cell receptors and methods of use therefor
JP2022505107A (ja) キメラ分子
CN118515748A (zh) 靶向kras g12突变的抗原结合蛋白及其用途
JP2022526720A (ja) キメラ抗原受容体の代替の細胞内シグナル伝達ドメイン
Kung et al. Induction of transgene-specific immunological tolerance in myeloablated nonhuman primates using lentivirally transduced CD34+ progenitor cells
EP4534554A1 (en) Mage-a1 specific tcr and use thereof
WO2024149347A1 (zh) 抗原结合蛋白及其用途
WO2019197671A1 (en) Mammalian mhc peptide display as an epitope selection tool for vaccine design
JP2024535781A (ja) 抗原結合タンパク質およびその使用
CN118344478A (zh) 抗原结合蛋白及其应用
HK40123852A (en) Mage-a1 specific tcr and use thereof
US20220273714A1 (en) T-cell receptors and methods of use thereof
WO2026046995A1 (en) T cell receptors and uses thereof
CN119432922A (zh) 一种用于展示天然构象的hla多肽的慢病毒或细胞、及其制备方法和应用
Hampton Identification and Characterization of Tumor Antigens Associated with Breast Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221014

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240529